KYTX
What one share of Kyverna Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. Our mission is to liberate patients from autoimmune diseases through the curative potential of cell therapy.
Kyverna Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.88 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$3.00 |
| Cash and investments | $3.24 |
| Debt | $0.41 |
| Book value | $2.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | — | −$89.61 | $0.92 | −$78.73 | — | −$10.51 |
| 2024 | — | −$3.33 | $0.06 | −$3.04 | — | $6.17 |
| 2025 | — | −$3.64 | $0.00 | −$3.47 | — | $3.85 |